Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
032300.KQ
STRONG SELLKOREA PHARMA Co., Ltd. · Healthcare · South Korea · $63M · Avg Vol: $141K/d
12
StockRankQ
40
V
33
M
24
P/E (TTM)
—
ROE
-3.5%
D/E
0.6x
Dividend %
0.6%
COMPANY DESCRIPTION
KOREA PHARMA Co., Ltd. . produces pharmaceutical drugs. The company offers amino acid, antibiotic, antidotal, antiepileptic, antihistamine, anti-inflammatory, antimicrobial, antiplatelet, circulatory system, CNS, dermatological, endocrine, gastrointestinal, hepatic, hormonal, respiratory,...
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 53M | 55M | 54M | 58M | 2.6% |
| EPS | -0.07 | 0.01 | 0.23 | -0.16 | 4250.0% |
| Shares | 11M | 11M | 11M | 11M | 0.0% |
| Debt | 36M | 23M | 15M | 26M | -10.7% |
| Equity | 39M | 45M | 47M | 45M | 4.8% |
| Op CF | 5M | 3M | 5M | 2M | -31.3% |
| Inv CF | -34M | 30M | -8M | -5M | — |
| Fin CF | -3M | -11M | -10M | 7M | — |
Loading...
PRICE (1M)-18.6%
SMA 50SMA 200
Close
$5.91
RSI (14)
38.3
52W High
$12.27
From 52W High
0.5%
SCORE BREAKDOWN
Quality
40
ROIC
-1.4%42.7
ROE
-3.5%40.6
GP/Assets
24.9%56.5
Op. Margin
5.3%55.2
FCF/Assets
-10.9%26.9
Piotroski
—55.7
Int. Cover
-0.3x39.0
D/E Ratio
0.58x28.3
Current Ratio
1.14x14.2
Value
33
P/E (TTM)
—N/A
EV/EBITDA
36.8x8.9
P/FCF
—N/A
P/B
1.4x69.3
P/S
1.0x82.9
Div Yield
0.6%17.5
Momentum
24
52W High %
48%21.3
RS 6M
-154%2.7
SMA 50/200
0.84x19.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
33%70.4
FUNDAMENTALS
Market Cap
$63M
P/E (Forward)
—
Gross Margin
34.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 032300.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 032300.KQ | KOREA PHARMA Co., Ltd.(you) | $63M | 12 | STRONG SELL |
| 063160.KS | CKD Bio Corp. | $62M | 15 | STRONG SELL |
| 092040.KQ | Amicogen, Inc. | $58M | 7 | STRONG SELL |
| 002390.KS | HANDOK Inc. | $73M | 17 | STRONG SELL |
| 183490.KQ | Enzychem Lifesciences Corporation | $55M | 18 | STRONG SELL |
| 000520.KS | Samil Pharmaceutical Co.,Ltd | $105M | 14 | STRONG SELL |
| 058820.KQ | CMG Pharmaceutical Co., Ltd. | $107M | 14 | STRONG SELL |
| 293780.KQ | AptaBio Therapeutics Inc. | $91M | 3 | STRONG SELL |
| 067080.KQ | DAE HWA Pharmaceutical Co., Ltd. | $127M | 7 | STRONG SELL |
| 003520.KS | Yungjin Pharm. Co., Ltd. | $158M | 10 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%